{"input_url":"https://www.sohu.com/a/1052284719_121157270","gnews_decode":"https://www.sohu.com/a/1052284719_121157270","http_status":200,"final_url":"https://www.sohu.com/a/1052284719_121157270","html_length":18414,"trafilatura_result":"ok","text_length":188,"text_preview":"7月20日，三星生物（Samsung Biologics）7月20日宣布，拟通过现金要约收购瑞士多肽药物原料药合同开发与生产企业PolyPeptide Group AG全部已发行股份，报价为每股44.31瑞郎，交易股权价值约14.6亿瑞郎。\n三星生物表示，此次收购将推动公司从抗体和抗体偶联药物（ADC）领域进一步拓展至多肽疗法，强化多模态CDMO（合同开发与生产组织）平台。","verdict":"OK"}